This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients (Ovrescancer)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: June 28, 2009
Last updated: June 29, 2009
Last verified: June 2009
young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.

Condition Intervention
Infertility Biological: blood tests

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Anti mullerian hormone [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • antral follicle count [ Time Frame: 2 years ]
  • FSH [ Time Frame: 2 years ]
  • inhibin b [ Time Frame: 2 years ]
  • menstrual history [ Time Frame: 2 years ]
  • E2 and prog [ Time Frame: 2 years ]

Biospecimen Retention:   Samples Without DNA

Estimated Enrollment: 100
Study Start Date: June 2009
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cancer patients
women 5-45 yr olf pre and post chemotherapy
Biological: blood tests
time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy

Detailed Description:
our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.

Ages Eligible for Study:   5 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
females 5-45 years old

Inclusion Criteria:

  • all females prior and after chemotherapy

Exclusion Criteria:

  • do not consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00930501

Contact: Ariel Revel, MD 97226776424

Hadassah Recruiting
Jerusalem, Israel
Contact: Ariel Revel, MD    97226776424   
Principal Investigator: Ariel Revel, MD         
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Responsible Party: Ariel Revel, MD, Hadassah Identifier: NCT00930501     History of Changes
Other Study ID Numbers: 111222
Study First Received: June 28, 2009
Last Updated: June 29, 2009

Keywords provided by Hadassah Medical Organization:
ovarian reserve
patients exposed to chemotherapy

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female processed this record on September 21, 2017